Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 39,752	$ 3,193
Property, plant and improvements
Property and equipment, net	161,913	166,509
Other assets
Operating lease right-of-use assets	251,110
Other receivable	417,904	418,905
Note receivable – related party	44,859	44,859
Advances to CEN Biotech Ukraine LLC – related party	905,328	875,328
Intangible assets, net	5,699,568	5,805,771
Total assets	7,520,434	7,314,565
Current liabilities
Accounts payable	206,521	206,521
Loans payable	10,113,095	10,107,205
Loans payable – related parties	1,361,550	1,360,806
Convertible notes payable	4,190,461	3,597,760
Convertible notes payable – related parties	926,368	926,368
Accrued interest	7,544,199	6,860,494
Accrued interest – related parties	1,032,171	946,227
Operating lease liabilities	40,683
Accrued expenses	446,432	402,377
Total current liabilities	25,861,480	24,407,758
Operating lease liabilities, less current portion	210,838
Patent acquisition liability	1,010,000	1,010,000
Convertible notes, less current portion	1,117,123	1,545,887
Convertible notes – related parties, less current portion	1,612,313	1,612,313
Total liabilities	29,811,754	28,575,958
Commitments and contingencies	0	0
Shareholders’ deficit
Common stock; unlimited authorized shares; 25,518,363 and 25,473,363 issued and outstanding as of March 31, 2019 and December 31, 2018, respectively. No par value.
Additional paid-in capital	14,606,510	14,393,660
Accumulated deficit	(36,897,830)	(35,655,053)
Total shareholders’ deficit	(22,291,320)	(21,261,393)
Total liabilities and shareholders’ deficit	$ 7,520,434	$ 7,314,565